Catalyst (CPRX) Announces Organizational Changes and CEO McEnany's Term Extension
More News related to CPRX
- Catalyst Receives Guidance from Nasdaq Regarding Minimum Bid Price Requirement
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
More News related to Management Changes
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
- Trading Radar for 12/1: Staples (SPLS), Universal Tech (UTI), Beacon Roofing (BECN) Report
- Unusual 11 Mid-Day Movers 11/30: SOMX, CLWT, KBX, CSGS Higher; AIG, BGP, BONT, HEB Lower
- Notable ETF Movers: SLX, EWJ, USO Higher; UNG, XRT Lower
- Best of the Web 11/30: Some Banks So Bad Buyers Won't Touch 'Em, Risky Bets Hurt Harvard, Eurozone Inflation Turns Positive
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) today announced two organizational changes and the extension of the term of Patrick J. McEnany's employment agreement with the Company for an additional two years, from November 8, 2009 to November 8, 2011.
Steven R. Miller, Ph.D, will become Catalyst's Chief Scientific Officer. Dr. Miller is currently Catalyst's Vice President of Pharmaceutical Development and Project Management
Jack Weinstein Catalyst's business development activities. Mr. Weinstein Is currently Catalyst's Vice President, Treasurer, and CFO.
Related Categories
Management ChangesStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
